Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 8/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392236 | 0.94 | ENPP1 (0.68) | ENPP1EGFRCSF1RSRCLCK | |
| SCHEMBL10945990 | 0.87 | EGFR (0.52) | ENPP1EGFRCSF1RLCKRET | |
| SCHEMBL10940331 | 0.87 | EGFR (0.52) | ENPP1EGFRCSF1RLCKRET | |
| SCHEMBL14403187 | 0.84 | ENPP1 (0.53) | ENPP1EGFRCSF1RSRCLCK | |
| SCHEMBL1259963 | 0.84 | ENPP1 (0.53) | ENPP1EGFRCSF1RSRCLCK | |
| SCHEMBL7597120 | 0.84 | ENPP1 (0.47) | ENPP1EGFRKDR | |
| SCHEMBL10947090 | 0.84 | ENPP1 (0.47) | ENPP1EGFRKDR | |
| SCHEMBL24392084 | 0.83 | ENPP1 (0.43) | ENPP1EGFRCSF1RSRCACHE | |
| SCHEMBL24392070 | 0.81 | EGFR (0.50) | EGFRCSF1RLCKKDM4EHTT | |
| SCHEMBL2476964 | 0.78 | RET (0.55) | ENPP1EGFRSRCLCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-4146621-A | ISOXAZOLO- OR PYRAZOLOPYRIDINES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
| US-4144332-A | USING AN ANILINO-NICOTINIC ACID | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1979-03-13 | — | — | US | disclosed |
| US-4141976-A | XANTHINES OR THIOXANTHINES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1979-02-27 | — | — | US | disclosed |
| US-4107306-A | OXO-BENZOTHIOPHENES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1978-08-15 | — | — | US | disclosed |
| US-4034087-A | TREATING PROLIFERATIVE SKIN DISEASES WITH 4-BENZYL-2-IMIDAZOLIDONES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1977-07-05 | — | — | US | disclosed |
| US-3800039-A | ANTITHROMBOGENIC PROCESS EMPLOYING SUBSTITUTED 6,7-DIALKOXYQUINAZOLINES | MEAD JOHNSON & CO | 1974-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ENPP1 4862/4885EGFR 4182/4885CSF1R 2651/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | ENPP1 972/4885EGFR 3421/4885CSF1R 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.